Paolo Gresele

Q: What Schools Are Affiliated With Paolo Gresele

Paolo Gresele is affiliated with the following schools: University of Milan, KU Leuven, University of Perugia, University of Florence, King's College London

Paolo Gresele's AcademicInfluence.com Rankings

Paolo Gresele

Physics

#7132

World Rank

#9144

Historical Rank

physics Degrees

Download Badge

Physics

Paolo Gresele's Degrees

PhD Physics University of Milan
Masters Physics University of Milan
Bachelors Physics University of Milan

Why Is Paolo Gresele Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Paolo Gresele's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome (2010) (512)
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. (2018) (491)
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. (2011) (390)
MYH9-Related Disease: May-Hegglin Anomaly, Sebastian Syndrome, Fechtner Syndrome, and Epstein Syndrome Are not Distinct Entities but Represent a Variable Expression of a Single Illness (2003) (306)
THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS (1985) (302)
COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). (2020) (286)
Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. (2003) (259)
Whole-genome sequencing of patients with rare diseases in a national health system (2020) (239)
Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. (2003) (234)
Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. (1997) (232)
Anti-platelet therapy: phosphodiesterase inhibitors. (2011) (230)
Platelets are essential for leukocyte recruitment in allergic inflammation. (2003) (221)
Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. (2005) (214)
Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH (2015) (206)
Position of nonmuscle myosin heavy chain IIA (NMMHC‐IIA) mutations predicts the natural history of MYH9‐related disease (2008) (174)
Effects of resveratrol and other wine polyphenols on vascular function: an update. (2011) (169)
A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. (2016) (159)
Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. (2008) (157)
Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. (2004) (157)
PROLONGING PROSTACYCLIN PRODUCTION BY NAFAZATROM OR DIPYRIDAMOLE (1984) (156)
Allergen induces the migration of platelets to lung tissue in allergic asthma. (2008) (153)
Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis (2003) (153)
MYH9‐Related Disease: A Novel Prognostic Model to Predict the Clinical Evolution of the Disease Based on Genotype–Phenotype Correlations (2014) (152)
Dipyridamole Inhibits Platelet Aggregation in Whole Blood (1983) (145)
Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey (2014) (138)
Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. (2010) (137)
HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction (2009) (135)
Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. (2011) (134)
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine (2020) (131)
Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. (2003) (126)
Platelets in Thrombotic and Non‐Thrombotic Disorders (2003) (125)
Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. (1987) (125)
Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. (1991) (123)
Platelet “first responders” in wound response, cancer, and metastasis (2017) (121)
Mechanism of the Antiplatelet Action of Dipyridamole in Whole Blood: Modulation of Adenosine Concentration and Activity (1986) (117)
Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. (2014) (116)
Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. (1992) (111)
Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples (2007) (110)
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. (1998) (104)
Endothelial dysfunction in patients with spontaneous venous thromboembolism. (2007) (101)
Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. (1984) (97)
Whole genome sequencing of a sporadic primary immunodeficiency cohort (2018) (92)
Thrombolytic Therapy for Thromboembolism of Vertebrobasilar Artery (1983) (87)
Platelets Release their Lysosomal Content In Vivo in Humans upon Activation (2000) (87)
Bleeding risk of surgery and its prevention in patients with inherited platelet disorders (2017) (86)
Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo (2009) (86)
Characterization of N,N’-bis(3-Picolyl)-4-Methoxy-Isophtalamide (Picotamide) as a Dual Thromboxane Synthase Inhibitor/Thromboxane A2 Receptor Antagonist in Human Platelets (1989) (86)
Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study (2013) (84)
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk (2020) (81)
Altered platelet function associated with the bronchial hyperresponsiveness accompanying nocturnal asthma. (1993) (81)
A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders (2015) (79)
Endothelial and platelet function alterations in HIV-infected patients. (2012) (78)
Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. (1993) (78)
BM 13.177, A SELECTIVE BLOCKER OF PLATELET AND VESSEL WALL THROMBOXANE RECEPTORS, IS ACTIVE IN MAN (1984) (75)
Endothelium, venous thromboembolism and ischaemic cardiovascular events (2009) (75)
Endogenous Nitric Oxide Acts as a Natural Antithrombotic Agent In Vivo by Inhibiting Platelet Aggregation in the Pulmonary Vasculature (1999) (74)
Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level Functional and modelling studies (2009) (72)
Platelets in Thrombotic and Non‐Thrombotic Disorders: pathophysiology, pharmacology and therapeutics (2002) (70)
In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients (2013) (70)
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. (2015) (69)
Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. (2000) (67)
Intraplatelet signaling mechanisms of the priming effect of matrix metalloproteinase‐2 on platelet aggregation (2005) (67)
Dominant inheritance of a novel integrin β3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families (2009) (67)
Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. (2008) (65)
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia (2014) (65)
Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. (2011) (64)
Novel approaches to the treatment of thrombosis. (2002) (61)
Platelet amyloid precursor protein is a modulator of venous thromboembolism in mice. (2017) (61)
Neutrophil more than platelet activation associates with thrombotic complications in COVID-19 patients (2020) (61)
Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. (2013) (60)
Alteration of Liver Enzymes Is a Feature of the Myh9-Related Disease Syndrome (2012) (60)
Outside-In Signalling Generated by a Constitutively Activated Integrin αIIbβ3 Impairs Proplatelet Formation in Human Megakaryocytes (2012) (59)
RhoA signaling through platelet P2Y₁ receptor controls leukocyte recruitment in allergic mice. (2015) (58)
PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention (2019) (57)
Leukotriene B4 production by stimulated whole blood: comparative studies with isolated polymorphonuclear cells. (1986) (56)
A novel mechanism regulating human platelet activation by MMP-2-mediated PAR1 biased signaling. (2017) (56)
Inherited Platelet Function Disorders: Algorithms for Phenotypic and Genetic Investigation (2016) (55)
Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019 (2020) (53)
Platelet activation and allergic asthma. (1982) (53)
A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. (2007) (52)
A novel nitric oxide‐releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression 1 (2005) (52)
Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial (2019) (51)
Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. (2009) (51)
Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. (2006) (50)
Diagnosis of platelet-type von Willebrand disease by flow cytometry (2010) (50)
Evidence for separate effects of U73122 on phospholipase C and calcium channels in human platelets. (1998) (50)
Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. (2012) (50)
Thromboxane Synthase Inhibition Combined with Thromboxane Receptor Blockade: A Step Forward in Antithrombotic Strategy? (1984) (49)
Curated disease‐causing genes for bleeding, thrombotic, and platelet disorders: Communication from the SSC of the ISTH (2019) (49)
Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC (2019) (49)
Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. (1988) (49)
Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells. (1998) (48)
Modeling CD40-Based Molecular Communications in Blood Vessels (2014) (48)
Platelets release active matrix metalloproteinase‐2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin (2007) (48)
Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia (2016) (48)
Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication (2007) (47)
Nitric oxide-enhancing or -releasing agents as antithrombotic drugs. (2019) (45)
NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. (2007) (45)
Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice (2005) (44)
Platelet Activation Markers in Patients with Peripheral Arterial Disease (1997) (44)
Matrix metalloproteinases and peripheral arterial disease (2010) (44)
Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). (2009) (43)
Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide–Donating Agent (2010) (43)
Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca(2+)-dependent tyrosine kinase Pyk2. (2013) (42)
PLATELETS AND ASTHMA (1985) (41)
C-reactive protein induces expression of matrix metalloproteinase-9: a possible link between inflammation and plaque rupture. (2013) (41)
Impaired superoxide anion, platelet-activating factor, and leukotriene B4 synthesis by neutrophils in cirrhosis. (1993) (40)
Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand’s disease by flow cytometry (2007) (40)
Prostaglandin Endoperoxides and Thromboxane A2 Activate the same Receptor Isoforms in Human Platelets (2002) (40)
Tranexamic acid, intrauterine contraceptive devices and fatal cerebral arterial thrombosis (1982) (38)
A new case of acquired Glanzmann's thrombasthenia: Diagnostic value of flow cytometry (2008) (38)
Picotamide Protects Mice from Death in a Pulmonary Embolism Model by a Mechanism Independent from Thromboxane Suppression (1990) (37)
Ankle-brachial index measured by palpation for the diagnosis of peripheral arterial disease. (2008) (37)
Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report (2019) (35)
Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome (2013) (34)
Platelets in hematologic and cardiovascular disorders : a clinical handbook (2007) (33)
Stimulation of Platelet Nitric Oxide Production by Nebivolol Prevents Thrombosis (2014) (33)
Platelet-targeted pharmacologic treatments as anti-cancer therapy (2017) (33)
Matrix Metalloproteinases and Platelet Function. (2017) (33)
Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry (2018) (32)
Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET). (2021) (31)
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). (2010) (30)
Simulating an in vitro experiment on nanoscale communications by using BiNS2 (2013) (30)
Binding and Release of Cytochrome c in Brain Mitochondria Is Influenced by Membrane Potential and Hydrophobic Interactions with Cardiolipin (2004) (30)
Interferon-Alpha Is Effective in the Treatment of HIV-1Related, Severe, Zidovudine-Resistant Thrombocytopenia: A Prospective, Placebo-controlled, Double-Blind Trial (1994) (30)
Mechanisms of thrombocytopenia in platelet-type von Willebrand disease (2019) (30)
Visualization of nitric oxide production by individual platelets during adhesion in flowing blood. (2015) (30)
Direct and Irreversible Inhibition of Cyclooxygenase-1 by Nitroaspirin (NCX 4016) (2005) (29)
The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits (1993) (28)
Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH (2016) (27)
TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival. (2008) (27)
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two‐year outcomes after the study closure (2020) (26)
Evidence for platelet activation in allergic asthma. (1987) (26)
Effect of substituted stilbenes on platelet function. (2015) (26)
De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures (2018) (26)
Effect of pentoxifylline on platelet aggregation. (1981) (26)
Next‐generation sequencing for the diagnosis of MYH9‐RD: Predicting pathogenic variants (2019) (25)
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. (2021) (25)
Endothelial dysfunction in patients with kidney failure and vascular risk factors: acute effects of hemodialysis. (2004) (25)
Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition. (2001) (25)
Antiplatelet agents in clinical practice and their haemorrhagic risk. (2013) (25)
Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives (2006) (25)
Partial isolation and function of the prostacyclin regulating plasma factor. (1985) (24)
Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake. (2011) (24)
Inhibitors of the interaction between von Willebrand factor and platelet GPIb/IX/V. (2012) (24)
Prochemerin cleavage by factor XIa links coagulation and inflammation. (2018) (24)
Platelet function assays in diagnosis: an update (2019) (24)
Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease (2016) (24)
Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin (2011) (23)
Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation (2014) (23)
Platelets Contribute to the Accumulation of Matrix Metalloproteinase Type 2 in Synovial Fluid in Osteoarthritis (2017) (23)
Laboratory diagnosis of clinically relevant platelet function disorders (2018) (23)
Search for SARS-CoV-2 RNA in platelets from COVID-19 patients (2020) (23)
Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome (2020) (22)
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Does not Inhibit In Vitro Thrombolysis by Pharmacological Concentrations of t-PA (2001) (22)
Nitric oxide and its antithrombotic action in the cardiovascular system. (2005) (22)
A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. (2019) (22)
Protein kinase C inhibitors enhance G‐protein induced phospholipase A2 activation in intact human platelets (1996) (22)
Salicylates Inhibit T Cell Adhesion on Endothelium Under Nonstatic Conditions: Induction of L-Selectin Shedding by a Tyrosine Kinase-Dependent Mechanism (2001) (21)
A novel congenital dysprothrombinemia leading to defective prothrombin maturation. (2014) (21)
Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome (2017) (21)
Effects of dietary protein restriction on albumin and fibrinogen synthesis in macroalbuminuric type 2 diabetic patients (2007) (20)
Activation of phospholipase A2 and beta-thromboglobulin release in human platelets: comparative effects of thrombin and fluoroaluminate stimulation. (1992) (20)
Contribution of matrix metalloproteinase 2 to joint destruction in group B Streptococcus-induced murine arthritis. (2012) (19)
Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study (2013) (19)
Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. (1985) (19)
Treatment of Intermittent Claudication with Mesoglycan – A Placebo-controlled, Double-blind Study (2001) (19)
Eltrombopag in preparation for surgery in patients with severe MYH9‐related thrombocytopenia (2019) (19)
Highly active antiretroviral therapy-related mechanisms of endothelial and platelet function alterations. (2014) (18)
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). (2019) (18)
Matrix metalloproteinases and peripheral arterial disease (2010) (17)
Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2. (2003) (17)
Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry (2018) (17)
Inherited platelet function disorders (2016) (16)
Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction? (2017) (16)
Bioactive lipid metabolism in platelet “first responder” and cancer biology (2018) (16)
Anti-platelet treatments in cancer: Basic and clinical research. (2018) (16)
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry (2020) (16)
Significant potentiation of anticoagulation by flu-vaccine during the season 2001-2002. (2003) (16)
Smoking and impaired endothelium-dependent dilatation. (1996) (16)
Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication. (2012) (15)
L-652,343, a novel dual cyclo/lipoxygenase inhibitor, inhibits LTB4-production by stimulated human polymorphonuclear cells but not by stimulated human whole blood. (1987) (14)
Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome (2021) (14)
COMBINING ANTIPLATELET AGENTS: POTENTIATION BETWEEN ASPIRIN AND DIPYRIDAMOLE (1985) (14)
New pyridazinone derivatives as inhibitors of platelet aggregation (1995) (14)
Inhibition of COX-1 activity and COX-2 expression by 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its semi-synthetic derivatives. (2011) (13)
Matrix metalloproteinase-2 on activated platelets triggers endothelial PAR-1 initiating atherosclerosis. (2021) (13)
Rossiello MR, Momi S, Caracchini R, et al. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression (2005) (13)
Effect of NSAIDs on pepsinogen secretion and calcium mobilization in isolated chief cells. (1995) (13)
Defective platelet β-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders (2006) (13)
Role of endothelial dysfunction in the thrombotic complications of COVID-19 patients (2020) (13)
Cloricromene inhibits leukotriene formation by human polymorphonuclear leucocytes by suppressing arachidonate release from membrane phospholipids. (1993) (13)
ERYTHROCYTE DEFORMABILITY CHANGES IN NORMAL PREGNANCY AND PRE‐ECLAMPSIA (1982) (13)
BM 13.177 selectively inhibits endoperoxide analogue induced vascular contractions. (1985) (13)
NCX4016: a novel antithrombotic agent. (2003) (12)
Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools. (2020) (12)
Platelet glycohydrolase activities: Characterization and release (1995) (12)
Thrombocytopenia in HIV infected patients. Prevalence and clinical spectrum. (1995) (12)
Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry (2019) (12)
Learning the Ropes of Platelet Count Regulation: Inherited Thrombocytopenias (2021) (11)
Guidance on the diagnosis and management of platelet‐type von Willebrand disease: A communication from the Platelet Physiology Subcommittee of the ISTH (2020) (11)
Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation (1996) (11)
Antivasoconstrictor and Antiaggregatory Activities of Picotamide Unrelated to Thromboxane A2 Antagonism (1997) (11)
Intrinsically Defective or Exhausted Platelets in Hairy Cell Leukemia? (1981) (11)
The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology (2021) (11)
Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH (2018) (11)
Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders. (2006) (11)
Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). (2018) (11)
Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction. (2011) (11)
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial (2011) (11)
A dichotomy in platelet activation: Evidence of different functional platelet responses to inflammatory versus haemostatic stimuli. (2018) (11)
Original Article: Albumin Prevents TxB, Formation from Thrombin-stimulated Human Platelets by Sequestering the Liberated Arachidonic Acid in the Extracellular Space. (1995) (11)
A novel variant Glanzmann thrombasthenia due to co-inheritance of a loss- and a gain-of-function mutation of ITGB3: evidence of a dominant effect of gain-of-function mutations (2018) (11)
Critical limb ischemia (2011) (10)
Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation. (1995) (10)
Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET). (2020) (10)
Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres (2015) (10)
Rivaroxaban Plasma Levels and Levetiracetam: A Case Report (2020) (10)
PAF levels in saliva are regulated by inflammatory cells. (1998) (10)
The peripheral arterial disease subgroup in the CHARISMA trial: does it tell us anything new? (2008) (10)
Assessment of Occlusion of the Vascular Access in Patients on Chronic Hemodialysis: Comparison of Physical Examination with Continuous-Wave Doppler Ultrasound (1999) (10)
Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients. (2018) (9)
Infusion of vincristine-loaded platelets in acute ITP refractory to steroids: an alternative to splenectomy. (1981) (9)
Potential anti-inflammatory effects of maraviroc in HIV-positive patients: A pilot study of inflammation, endothelial dysfunction, and coagulation markers (2014) (9)
Prevalence of hemostatic alterations in patients with recurrent spontaneous subconjunctival hemorrhage (2016) (9)
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study (2015) (9)
Laboratory investigation of platelets (2001) (9)
The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade. (1993) (9)
Matrix metalloproteinase-2 enhances platelet deposition on collagen under flow conditions (2015) (9)
Mucus-secreting 'signet-ring' cells in CSF revealing the site of primary cancer. (1980) (9)
Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology (2021) (9)
Heparin in the prophylaxis and treatment of venous thromboembolism and other thrombotic diseases. (2012) (9)
Dipyridamole Inhibits Leukotriene B4 Synthesis (1987) (9)
Plasma levels of beta(2)-microglobulin, a biomarker of peripheral arterial disease, are not affected by maximal leg exercise in patients with intermittent claudication. (2009) (9)
Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding. (2022) (9)
Impact of COVID-19 and COVID-19 vaccination on high-risk patients with Antiphospholipid Syndrome: a nationwide survey (2022) (8)
The platelet count in EDTA‐anticoagulated blood from patients with thrombocytopenia may be underestimated when measured in routine laboratories (2012) (8)
A comprehensive high-throughput sequencing test for the diagnosis of inherited bleeding, thrombotic and platelet (2015) (8)
Response: MMP-9 in platelets: maybe, maybe not (2011) (8)
Choline plasmalogen biosynthesis by transmethylation in human platelets. (1987) (8)
Thromboxane A2 and prostacyclin do not modulate the systemic hemodynamic response to cold in humans. (1985) (8)
Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath? (2004) (8)
Apparent genotype–phenotype mismatch in a patient with MYH9-related disease: When the exception proves the rule (2013) (8)
Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome (2021) (8)
[Italian intersocietary consensus document on aspirin therapy in primary cardiovascular prevention]. (2014) (7)
Vaccine-induced massive pulmonary embolism and thrombocytopenia following a single dose of Janssen Ad26.COV2.S vaccination (2022) (7)
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study (2021) (7)
Effect of First Long-Term Training on Whole Blood Count and Blood Clotting Parameters in Thoroughbreds (2021) (7)
Anti‐severe acute respiratory syndrome coronavirus‐2 adenoviral‐vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers (2022) (7)
Vincristine-loaded platelets for autoimmune thrombocytopenic purpura (letter) (1982) (7)
The Migration of Platelets and their Interaction with Other Migrating Cells (2017) (7)
Thromboxane does not play a significant role in acute, cold-induced vasoconstriction in Raynaud's phenomenon. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. (1992) (7)
Spontaneous hemarthrosis in combined Glanzmann thrombasthenia and type 2N von Willebrand disease (2014) (7)
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: From the START antiplatelet registry. (2020) (7)
Acetylsalicylic acid, BM 13.177 and picotamide improve the survival of endotoxin-infused rabbits. (1988) (7)
Vinca-loaded platelets. (1984) (7)
Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life (2000) (7)
PLATELET INHIBITORY ACTIVITY OF PROSTACYCLIN IN THE PRESENCE OF ERYTHROCYTES AS STUDIED WITH THE IMPEDANCE AGGREGOMETER (1984) (7)
Influence of products of the cyclo-oxygenase pathway on platelet shape change (1985) (6)
Selective Cytochrome c Displacement by Phosphate and Ca2+ in Brain Mitochondria (2006) (6)
Reasons for Visits to an Emergency Center and Hemostatic Alterations in Patients with Recurrent Spontaneous Subconjunctival Hemorrhage (2016) (6)
Coinheritance of three novel FV gene mutations in a patient with a severe FV deficiency (2012) (6)
Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study (2019) (6)
Evidence that cytosolic phospholipase A2 is down‐regulated by protein kinase C in intact human platelets stimulated with fluoroaluminate (1999) (6)
Effect of statins on measures of coagulation: potential role of low-density lipoprotein receptors. (2018) (6)
Endogenous antiaggregatory prostaglandins can contribute to inhibition of hemostasis: a pharmacological study in vivo in humans. (1987) (6)
Splenic irradiation versus splenectomy for severe, refractory HIV-related thrombocytopenia: effects on platelet counts and immunological status. (2000) (6)
Involvement of platelets in experimental mouse trypanosomiasis: evidence of mouse platelet cytotoxicity against Trypanosoma equiperdum. (2000) (6)
Role of Increased Lipoprotein (a) in Retinal Vein Occlusion: A Systematic Review and Meta-analysis (2021) (6)
Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma (2020) (6)
Pleiotropic effects of PCSK9-inhibition on hemostasis: Anti-PCSK9 reduce FVIII levels by enhancing LRP1 expression. (2022) (6)
Cloricromene inhibits G-protein-mediated activation of phospholipase A2 in human platelets. (1993) (6)
Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET). (2022) (6)
Responder-nonresponder behavior of human-platelets towards thromboxane synthase inhibitors (tsi) is due to difference in adenylate-cyclase sensitivity (1985) (5)
Interactions between thrombophilic genetic mutations and clinical bleeding in patients on chronic oral anticoagulant treatment. (2005) (5)
760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry (2021) (5)
Comprar Platelets in Hematologic and Cardiovascular Disorders. A Clinical Handbook | Jos Vermylen | 9780521881159 | Cambridge University Press (2007) (5)
Platelets and Airway Diseases (2017) (5)
Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry (2019) (4)
Deficiency of matrix metalloproteinase-2 (MMP-2) protects mice against platelet-dependent thrombosis (2004) (4)
In vitro and ex vivo effects of indobufen on red blood cell deformability (2004) (4)
Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders. (1991) (4)
The role of platelets, neutrophils and endothelium in COVID-19 infection (2022) (4)
Extrapolation of trial results suggests that aspirin is useful in intermittent claudication (1998) (4)
Acquired von Willebrand syndrome type 2A in a JAK2-positive essential thrombocythaemia -affected member of a large von Willebrand disease family with a novel autosomal dominant A1716P mutation (2011) (4)
Surface bound mediators on platelets are required for pulmonary eosinophil recruitment in a murine model of allergic inflammation: a role for platelet p-selectin. (2005) (4)
Expanding the genetic spectrum of TUBB1-related thrombocytopenia (2021) (4)
Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs. (2017) (4)
Liquid nitrogen snap frozen saphenous vein for vascular access in dialysis. (1991) (4)
Inherited Disorders and Gene Regulation of Platelet Signal Transduction: The Picture Is Expanding (2001) (4)
Red cell deformability alterations in normal late pregnancy: possible role of plasma components. (1991) (4)
Usefulness of lyophilized calibration plasmas for International Normalized Ratio determination with the bovine combined thromboplastin (Thrombotest): results of a collaborative study (2005) (4)
Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer (2020) (4)
The Post-thrombotic Syndrome-Prevention and Treatment: VAS-European Independent Foundation in Angiology/Vascular Medicine Position Paper (2022) (4)
Matrix metalloprotease 3 (MMP3) inhibition effect of a viscosupplement based on a hyaluronic acid amide derivative (HYADD4) (2018) (3)
Lack of synergism between dazoxiben and dipyridamole following administration to man. (1985) (3)
Direct and irreversible inhibition of cyclooxygenase-1 ( COX-1 ) by nitroaspirin ( NCX 4016 ) (2005) (3)
Platelets in Hematologic and Cardiovascular Disorders: Preface (2007) (3)
Platelets and Matrix Metalloproteinases: A Bidirectional Interaction with Multiple Pathophysiologic Implications (2021) (3)
Clotting activation after blood transfusion in patients receiving 5-fluorouracil and mitomycin-C treatment (2004) (3)
Possible role of platelet activation in the cardiovascular complications associated with HIV infection: differential effects of abacavir (ABC) vs. tenofovir (TDF) (2011) (3)
5-ASA-glutamate protects rats from inflammatory bowel disease induced by intracolonic administration of trinitrobenzensulfonic acid. (1998) (3)
Mechanisms of allergy and clinical immunology RhoA signaling through platelet P2Y1 receptor controls leukocyte recruitment in allergic mice (2017) (3)
Multicentre evaluation of 5B9, a monoclonal anti-PF4/heparin IgG mimicking human hit antibodies, as an internal quality control in hit functional assays: communication from the isth ssc subcommittee on platelet immunology. (2021) (3)
Inhibition of platelet function after ocular administration of non-steroidal anti-inflammatory drugs. (2019) (3)
Higher levels of plasma matrix metalloproteinase-2 are associated with a significantly increased risk of arterial thrombosis in patients with the antiphospholipid syndrome. (2012) (3)
The EHA Research Roadmap: Platelet Disorders (2021) (3)
Platelet Thromboxane A2 Receptor Number and Function in Normal and Hypertensive Pregnancy (1993) (3)
Germline GATA2 variant disrupting endothelial eNOS function and angiogenesis can be restored by c-Jun/AP-1 upregulation (2021) (3)
Effect of glyceryl trinitrate on distensibility of peripheral muscular arteries in humans is not mediated by prostaglandins. (1991) (3)
ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers (2021) (3)
In vitro effect of anti-β₂ glycoprotein I antibodies on P-selectin expression, a marker of platelet activation. (2012) (3)
Platelets in Thrombotic and Non-thrombotic Disorders: Platelets and chemotaxis (2002) (2)
Platelets activated locally in vivo regulate prostacyclin production by vessel wall (1985) (2)
Early onset life-threatening myelosuppression after low dose of intravesical thiotepa (1982) (2)
Whole-genome sequencing of a sporadic primary immunodeficiency cohort (2020) (2)
Coronary and peripheral artery atherosclerosis: what choice for antiplatelet therapy (2018) (2)
Antiplatelet Agents (2012) (2)
Platelet-derived nitric oxide (NO) is suppressed by hyperhomocysteinemia: a possible prothrombotic effect (2003) (2)
Dipyridamole inhibits platelet-aggregation in whole-blood invitro and exvivo (1983) (2)
Platelets in Thrombotic and Non-thrombotic Disorders: Editors' preface (2002) (2)
FVIII/VWF complex displays a greater pro‐haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell‐based models (2020) (2)
Perioperative handling of antiplatelet therapy: watching the two sides of the coin (2009) (2)
Platelet lung thromboembolism after intravenous (iv) collagen plus epinephrine (coll+epi) in mice: characterization of the model (1990) (2)
Vincristine-loaded platelets for autoimmune thrombocytopenic purpura. (1982) (2)
Effects of the medium on the filterability of human red blood cells. (1990) (2)
Inherited platelet disorders in women. (2019) (2)
Antithrombotic Potential of Thromboxane Synthase Inhibitors: Problems and Possible Solutions (1985) (2)
Detrimental Effects of High-Dose Dexamethasone in Severe, Refractory, HIV-Related Thrombocytopenia (2000) (2)
Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir (2010) (2)
[Pregnancy and labor in a primigravida with Glanzmann's thrombasthenia]. (1994) (2)
Dipyridamole and PDE Inhibitors (2017) (2)
recruitment in a murine model of allergic inflammation Platelet P-selectin is required for pulmonary eosinophil and lymphocyte (2013) (2)
First Diagnosis of Hemophilia B in a Nonagenarian (2016) (1)
Walking-induced endothelial dysfunction predicts ischemic cardiovascular events in patients with intermittent claudication (2021) (1)
THU0194 Role of Platelets in the Pathogenesis of Osteoarthritis and Biological Effects of Hyaluronic Acid: in Vivo and in Vitro Study (2014) (1)
Platelet dysfunction in platelet-type von Willebrand disease due to the constitutive triggering of the Lyn-PECAM1 inhibitory pathway (2021) (1)
Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment (2022) (1)
Proline-rich tyrosine kinase Pyk2 regulates deep vein thrombosis (2022) (1)
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET. (2020) (1)
IMPACT OF PRIOR CHRONIC ANTIPLATELET THERAPY ON SHORT- AND LONG-TERM ADVERSE EVENTS IN PATIENTS PRESENTING WITH AN ACUTE CORONARY SYNDROME: INSIGHTS FROM THE ACUITY TRIAL (2010) (1)
Novel approaches to antiplatelet therapy. (2022) (1)
Possible incorrect genotyping of heterozygous factor V Leiden and Prothrombin 20210 gene mutations by the GeneXpert assay. (2014) (1)
β1-tubulin in human platelets: not simply a structural cell frame (2005) (1)
Ticagrelor versus Clopidogrel in high bleeding risk patients presenting with Acute Coronary Syndromes: insights from the multicenter START-ANTIPLATELET registry (2020) (1)
Publisher Correction: Whole-genome sequencing of a sporadic primary immunodeficiency cohort (2020) (1)
The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale (2020) (1)
Effect of body mass index on ischemic and bleeding events in patients presenting with acute coronary syndromes: insights from the START-ANTIPLATELET registry (2020) (1)
Long-term treatment with thalidomide for severe recurrent hemorrhage from intestinal angiodysplasia in Glanzmann Thrombasthenia (2020) (1)
Two novel ITGA2B mutations in a Glanzmann thrombasthaenia family associated with different platelet phenotypic expression. (2017) (1)
A p.Arg127Gln variant in GPIbα LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD (2021) (1)
Release of MMP-2 in the circulation of patients with acute coronary syndromes undergoing percutaneous coronary intervention: Role of platelets. (2022) (1)
Prostaglandin E , Potentiates Platelet Aggregation by Priming Protein Kinase C (2003) (1)
The amazing genetic complexity of anucleated platelets (2022) (1)
Reorientation of cyclic endoperoxide metabolism and efficacy of thromboxane synthetase inhibitors (tsi) (1983) (1)
A novel mechanism regulating human platelet activation by MMP-2 mediated PAR 1 biased signaling Running title : MMP-2 cleaves PAR 1 triggering biased signaling (2016) (1)
Review for "NMD Efficiency Influences Bleeding Severity in ITGA2B c. 2659C >T (p. Q887X ) Knock‐in Mice" (2021) (0)
A nitric oxide-donor pravastatin hybrid drug exerts antiplatelet and antiatherogenic activity in mice (2022) (0)
Schmidt,a memorial lecture - peroxides in hemostasis and thrombosis (1985) (0)
Manipulation of Pro- and Antiaggregating Prostaglandins: New Antithrombotic Strategies (1985) (0)
Inhibition ofPAFsynthesis bystimulated human polymorphonuclear leucocytes withcloricromene, aninhibitor of phospholipase A2activation (1996) (0)
Tyrosine Kinase-Dependent Mechanism Induction of L-Selectin Shedding by a Endothelium Under Nonstatic Conditions: Salicylates Inhibit T Cell Adhesion on (2000) (0)
Bm-13.177 specifically blocks the platelet thromboxane receptor (1984) (0)
Bioactive lipid metabolism in platelet “first responder” and cancer biology (2018) (0)
Ultraviolet spectra of membrane-rich human platelet particulates (1982) (0)
Effects of the stereoisomers of indobufen (IB) on erythrocyte filterability (EF) (1990) (0)
Defective release and reduced total content of α and δ platelet (plt) granules in cirrhotic patients (C) is associated with in vivo platelet activation (1990) (0)
A novel pathway for the production of diglycerides (DG) in human platelets (plts) (1990) (0)
AD6 inhibits the liberation of arachidonate (AA) and β-TG release in fluoride-stimulated human platelets (1990) (0)
Preventing Integrin Activation Induced by Contact With Endothelial Cells Salicylates Inhibit Adhesion and Transmigration of T Lymphocytes by (2013) (0)
Usefulness of global tests of primary hemostasis in the initial screening of mild/moderate bleeding disorders for orienting towards von Willebrand disease or inherited platelet functions disorders. (2022) (0)
Ischemic and bleeding risk stratification in diabetic patients after acute coronary syndrome based on insulin requirement (2020) (0)
The role of the focal adhesion kinase PYK2 in platelet activation (2011) (0)
chronic allergic inflammation Platelets are necessary for airway wall remodeling in a murine model of (2013) (0)
High-on-treatment platelet reactivity predicts adverse outcome after carotid artery stenting: A prospective study. (2022) (0)
The Effects Of Apyase On Platelet And Leukocyte Migration Through Lung Tissue In A Murine Model Of Allergic Inflammation (2011) (0)
AB0952 Intra-articular low molecular weight hyaluronate reduces platelet influx and matrix metalloproteinase-2 levels in synovial fluid of patients with knee osteoarthritis (2013) (0)
Contents, Vol. 32, 1991 (1981) (0)
ID: 259 Prognostic value of TAFI level in patients with liver cirrhosis (2006) (0)
PLATELETS AND THROMBOPOIESIS Visualization of nitric oxide production by individual platelets during adhesion in ﬂ owing blood (2014) (0)
C0298: Antithrombotic and In Vivo Antiplatelet Activity of Nebivolol are Mediated by Increased Platelet-Derived Nitric Oxide (2014) (0)
The diagnostics of heparin-induced thrombocytopenia in Italy and the possible impact of vaccine-induced immune thrombotic thrombocytopenia on it (2022) (0)
Statin Therapy Reduces Carotid Atherosclerotic Plaque Matrix Metalloproteinase-2 Content and Adverse Cardiovascular Events in Patients Undergoing Endarterectomy (2019) (0)
The Role Of Platelet Matrix-Metalloproteinase 2 (MMP2) On Platelet And Leukocyte Migration Through Lung Tissue In A Murine Model Of Allergic Inflammation (2011) (0)
[Occult temporal arteritis. Case reports and review of the literature]. (1982) (0)
[The measurement of PAF (platelet activating factor) in human saliva: standardization of the method]. (1996) (0)
Major bleedings in mechanical prosthetic heart valves patients on Vitamin K antagonist treatment. Data from the PLECTRUM Study (2022) (0)
COVID-19 infection-associated platelet and neutrophil activation is blunted by previous anti-SARS-CoV-2 vaccination. (2023) (0)
Publisher Correction: Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data (2018) (0)
Guidance on the diagnosis and management of PT‐VWD: A communication from the platelet physiology subcommittee of the ISTH‐ REPLY to Comment on the disease’ nomenclature (2021) (0)
Platelets in Hematologic and Cardiovascular Disorders: Glossary (2007) (0)
Platelets and parasites (2002) (0)
Role of protein kinase C in the release of arachidocic acid from platelets (1999) (0)
Antithrombotic treatment for retinal vein occlusion: a systematic review and meta-analysis. (2022) (0)
SSC 2014 Milwaukee – Meeting Minutes (2014) (0)
Role of platelets in the pathogenesis of osteoarthritis and biological effects of hyaluronic acid: in vivo and in vitro study (2014) (0)
Randomized Trial of Hymovis® versus Synvisc® on Matrix Metalloproteinases in Knee Osteoarthritis (2020) (0)
Platelet “first responders” in wound response, cancer, and metastasis (2017) (0)
Development of an International Glossary for Clinical Guidelines Collaboration. (2023) (0)
Increased plasma PCSK-9 is associated with restenosis in patients undergoing carotid endarterectomy (2022) (0)
Prevalence of thrombophilic genetic mutations in patients undergoing thrombotic events while on oral anticoagulants: a case-control study (2003) (0)
Acquired von Willebrand syndrome type 2 A in a JAK 2-positive essential thrombocythaemia-affected member of a large von Willebrand disease family with a novel autosomal dominant A 1716 P mutation (2018) (0)
A platelet lipidomics signature in patients with COVID-19. (2023) (0)
Effect of different plasma expanders on erythrocyte filtrability (2016) (0)
Abstract 15758: Anti-Inflammatory and Anti-Atherogenic Activities of Ncx 6560, a Nitric Oxide (no)-Donating Statin, in Hypercholesterolemic Mice (2010) (0)
Rivaroxaban Plasma Levels and Levetiracetam (2020) (0)
Whole-genome sequencing of patients with rare diseases in a national health system (2020) (0)
Prochemerin Cleavage By Factor XIa Links Adipogenesis, Inflammation and Coagulation (2016) (0)
Active secretion of lysosomal glycohydrolases by activated human platelets “in vivo” studies on lysosomal release and molecular mechanisms regulating their secretion (1997) (0)
Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data (2018) (0)
Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology (2022) (0)
[Picotamide does not interfere with the anticoagulant activity of warfarin in patients wearing heart valve prostheses]. (1990) (0)
Thromboxane-synthase and thromboxane A2 antagonistic drugs (1992) (0)
Activated human protein c (aPC) protects mice from thrombin-induced thromboembolism via inhibition of endogenous thrombin formation rather than via stimulation of fibrinolysis (1994) (0)
Next‐generation sequencing for the diagnosis ofMYH9‐RD (2019) (0)
Of mice and men: genes relevant to thrombosis and bleeding. (2018) (0)
Thromboxane biosynthesis and platelet function in patients with peripheral arterial disease (PAD) (1992) (0)
Platelets in Thrombotic and Non-thrombotic Disorders: Plate section (2002) (0)
Th-P16:408 Nitropravastatin (NCX 6550) is more effective than pravastatin in preventing thrombus formation and intimal thickening in severe hyperlipidemic mice (2006) (0)
Comparative evaluation of the fully automated HemosIL® AcuStar ADAMTS13 activity assay vs. ELISA: possible interference by autoantibodies different from anti ADAMTS-13 (2020) (0)
Platelets in Thrombotic and Non-Thrombotic Disorders: Platelet signalling: tyrosine kinases (2002) (0)
Comprar Antiplatelet Agents | Paolo Gresele | 9783642294228 | Springer (2012) (0)
Blood platelets and Charles Darwin’s natural selection (2023) (0)
Duplex scanning in vascular disorders, (2nd edn.)By D E Strandness Jr. (Pp 329; $120.) New York: Raven Press, 1993. ISBN 0-7817-0014-0 (1995) (0)
Platelet-targeted pharmacologic treatments as anti-cancer therapy (2017) (0)
Vitamin B12 levels in patients with retinal vein occlusion and their relation with clinical outcome: a retrospective study (2022) (0)
Defective LTB4 prduction by whole blood and isolated polymorphonuclear cells in cirrhotics (C) (1990) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Paolo Gresele?

Paolo Gresele is affiliated with the following schools: